Vanguard Global Advisers’s Royalty Pharma RPRX Stock Holding History
Bought
Maintained
Sold
Other funds holding RPRX
Vanguard Global Advisers's RPRX Position: Q3 2026 in Review
Vanguard Global Advisers increased its Royalty Pharma (RPRX) stake by 14% in Q3 2026, buying an estimated $1.9M and bringing the position to 262,730 shares worth $15.3M. The position accounts for 0.01% of the portfolio, ranked #587.
Vanguard Global Advisers first reported a position in RPRX in Q1 2026 and has held it in 3 quarters since. 573 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.
- Vanguard Global Advisers held 262,730 shares of Royalty Pharma worth $15.3M as of Q3 2026.
- Vanguard Global Advisers bought 32,253 Royalty Pharma shares in Q3 2026, an estimated $1.9M.
- Royalty Pharma made up 0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #587 holding.
- Vanguard Global Advisers first reported a position in Royalty Pharma in Q1 2026 and has held it in 3 quarters since.
- 573 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.
Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.